American chemical industry news

• 

  30 April 2026

  Evonik expands Americas fast‑cure epoxy range with Ancamine 2868 and 2844

  New epoxy hardeners enable rapid thin-film cure and fast property build at low temps/high humidity, boosting formulation flexibility and corrosion/carbamation resistance for protective coatings
• 

  30 April 2026

  Johnson & Johnson names Ryan Koors VP, Investor Relations

  Effective May 7, 2026; reports to CFO Joseph J. Wolk; succeeds Darren Snellgrove (joining Halozyme). 20+ years at the firm across Innovative Medicine, R&D, MedTech and supply chain
• 

  30 April 2026

  BASF Q1 2026: resilient performance

  Solid volume growth offset currency headwinds; EBITDA before special items €2.4bn (vs €2.5bn). Sales slightly down; free cash flow -€1.375bn. Dividend €2.25; outlook unchanged.
• 

  30 April 2026

  Roche to present ophthalmology portfolio data at ARVO 2026

  ARVO 2026: real‑world data show Vabysmo reduces retinal fluid in nAMD/DME; Susvimo enables sustained delivery with lower treatment burden; early vamikibart IL‑6 results; 45+ abstracts.
• 

  30 April 2026

  Eli Lilly Q1 2026: Revenue up 56%, raises full‑year guidance

  EPS jumped ~170% reported (~156% non‑GAAP); volume growth offset lower realized prices; FDA approved oral GLP‑1 Foundayo; positive Phase‑3 readouts; four acquisitions announced
• 

  30 April 2026

  Merck & Co Q1 2026 Results — Sales Growth, Regulatory Approvals and Clinical Milestones

  Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16

• 

  29 April 2026

  Biosimilars: stricter expectations for elastomeric closures

  Originator-level assessment required (functionality, E&L, CCI). Supplier data can't replace system-level testing. Risks: format migration, dual-market filings. Adopt platform approach; decide early.
• 

  29 April 2026

  Genentech to present ophthalmology data at ARVO 2026

  ARVO presentations: real-world Vabysmo data show retinal drying in wet AMD/DME; Susvimo demonstrates sustained delivery and reduced treatment burden; vamikibart shows early efficacy; >45 abstracts
• 

  29 April 2026

  Novo Nordisk: Denecimig (Mim8) reduces annualised bleeding rate in haemophilia A regardless of inhibitor status

  Denecimig (Mim8) cut annualised bleeding rates in haemophilia A (with/without inhibitors) in Phase 3 FRONTIER2 for once-monthly/weekly dosing; well tolerated, no thromboembolic events
• 

  29 April 2026

  GSK Q1 2026 — Specialty Medicines Drive Growth

  Q1 sales £7.6bn (+5% CER); Specialty Medicines £3.2bn (+14%). Core operating profit +10%, Core EPS +9%. Strong cash generation; 17p Q1 dividend. 2026 guidance and >£40bn 2031 target reaffirmed.
• 

  29 April 2026

  INEOS Acetyls and Sandpiper partner on 1.1 MTPA low‑carbon methanol plant in Texas City

  FEED starts Q2 2026; FID targeted 2027; first production 2030. ~$1.7B capex. Up to 300,000 t/y to Acetic Acid. ~1,500 construction jobs, 25 permanent. CCS targets 97% capture.
• 

  29 April 2026

  UPM approves Plywood demerger to create listed WISA Group

  Board approved plan to spin off a business into a new listed company; EGM approval pending; 1:1 share distribution; target completion Oct 31, 2026; listing expected early Nov 2026.
• 

  29 April 2026

  UPM Q1 2026: Strong start led by decarbonization solutions

  Q1 sales €2,505m; comparable EBIT €274m (-5%); operating cash flow €89m; net debt €2,962m. Energy and biofuels strong. H1 comparable EBIT guidance €325–525m.
• 

  29 April 2026

  Neste Q1 2026 Interim Report

  Strong Q1: comparable EBITDA EUR 861m; cash flow before financing EUR 286m; renewable margin USD 856/t; oil refining margin USD 23.0/bbl; leverage 31.7%; volumes hit by maintenance
• 

  28 April 2026

  Plastic Ingenuity adopts PureCycle PureFive recycled PP for coffee lids

  Coffee lids now use 25-100% recycled polypropylene from a dissolution process; material retains virgin-like performance, has FDA food-contact clearance and GreenCircle certification.
• 

  28 April 2026

  GSK: FDA grants priority review and Breakthrough Therapy for bepirovirsen

  Phase III B-Well trials showed significantly higher functional cure rates and acceptable safety in chronic hepatitis B; drug is an antisense oligonucleotide; PDUFA date 26 Oct 2026
• 

  28 April 2026

  PPG Q1 2026 results

  Q1 net sales $3.93B (+7%), organic +1% on price. Adjusted EPS $1.83 (+6%). Segment margin 16%, EBITDA margin 19%. ~$100M buybacks. Reaffirms FY EPS $7.70–8.10.
• 

  28 April 2026

  UPM joint venture with Sappi enters EU Phase II merger review

  EC opened Phase II on 28 Apr 2026. The proposed graphic-paper JV needs approvals in other jurisdictions; parties are cooperating and say the deal strengthens European supply resilience.
• 

  28 April 2026

  Novo Nordisk to present Wegovy and next‑generation obesity data at ECO 2026

  Presenting 52 abstracts at ECO: data on semaglutide (injectable and oral), higher‑dose 7.2 mg, CagriSema combo, menopause effects, CV risk, weight‑loss timelines and real‑world outcomes.
• 

  28 April 2026

  PPG names Jamie Beggs SVP and CFO

  Starts July 6, succeeding retiring CFO Vince Morales after 41 years; will report to CEO Tim Knavish, lead corporate development and IT, bringing 25+ years of financial leadership.
• 

  28 April 2026

  BASF and Nutrien partner to expand farmer access to low‑carbon biofuel markets

  Farmers get agronomist support and digital tools to document low-carbon-intensity corn, connect with biorefineries, and access low-CI biofuel programs (e.g., Section 45Z).
• 

  28 April 2026

  Air Liquide Q1 2026: growth and record investments

  Q1 sales €6.8B (+3.4% ex-currency/energy). Gas & Services +2%; Healthcare +4%. Efficiencies €142M; operating cash flow +7%. Investments €1.5B, backlog €5.5B; DIG Airgas closed; +100bps margin target 2026.
• 

  28 April 2026

  Boehringer Ingelheim’s survodutide achieves 16.6% weight loss in Phase III obesity trial

  Trial met co-primary endpoints; 85.1% achieved ≥5% weight loss vs 38.8% placebo; weight loss mainly fat with reduced waist circumference; GI events were mild–moderate; MASH trials ongoing
• 

  28 April 2026

  bp Q1 2026 results

  Q1: upstream and downstream reliability rose; underlying RC profit $3.2B; operating cash flow $2.9B after $6.0B working-cap build; net debt $25.3B; Gelsenkirchen sale agreed.
• 

  27 April 2026

  GSK efimosfermin granted FDA Breakthrough and EMA PRIME for MASH

  Phase II data: once-monthly long-acting FGF21 candidate improved fibrosis and disease resolution in F2/F3, well tolerated; phase III underway and F4 trials planned; condition drives liver transplants
• 

  27 April 2026

  Johnson & Johnson’s IMAAVY granted FDA Priority Review for wAIHA

  FDA granted Priority Review to nipocalimab sBLA for warm autoimmune hemolytic anemia after Phase 2/3 ENERGY showed durable hemoglobin responses and fatigue improvement; review ~6 months.
• 

  27 April 2026

  Johnson & Johnson: FDA approves CAPLYTA sNDA to reduce schizophrenia relapse risk

  FDA approved sNDA for CAPLYTA (lumateperone) to prevent relapse in schizophrenia. Phase 3 randomized‑withdrawal: 63% lower relapse risk (HR 0.37); 84% relapse‑free at 6 months; safety consistent.
• 

  27 April 2026

  Lilly to acquire Ajax Therapeutics for AJ1‑11095, a first‑in‑class Type II JAK2 inhibitor

  Lead program in Phase 1; POC data due late 2026. Designed to deliver deeper, more durable responses than current Type I JAK2 therapies. Deal may pay up to $2.3B, subject to closing.
• 

  27 April 2026

  Momentive names Bob Waitt CCO

  Appointee joins from Elkem's silicones division after 12 years of global commercial leadership; will steer commercial strategy to boost revenue and market presence. Former Albright CEO; BS EE.
• 

  27 April 2026

  Veolia and Amazon to Use Reclaimed Water for Data Center Cooling

  Deploy containerized treatment to convert wastewater into cooling water for a Mississippi data center by 2027, reusing >83M gal/year; AI will optimize operations and scaling.